<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; chemotherapy</title>
	<atom:link href="http://oralcancernews.org/wp/tag/chemotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Cisplatin aids survival of high-risk head and neck cancer</title>
		<link>http://oralcancernews.org/wp/cisplatin-aids-survival-of-high-risk-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/cisplatin-aids-survival-of-high-risk-head-and-neck-cancer/#comments</comments>
		<pubDate>Sat, 04 Feb 2012 02:44:50 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[extracapsular spread]]></category>
		<category><![CDATA[margins]]></category>
		<category><![CDATA[nodes]]></category>
		<category><![CDATA[radiotherapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12412</guid>
		<description><![CDATA[Source: www.oncologyreport.com Author: Miriam E. Tucker Adding chemotherapy to radiotherapy improved 10-year survival of resectable head and neck carcinomas among high-risk patients who had microscopically involved resection margins and/or extracapsular spread of disease – but not in high-risk patients who only had tumor in multiple lymph nodes. The findings come from a long-term update and [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/cisplatin-aids-survival-of-high-risk-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Connected nodes in throat cancer signal poor prognosis</title>
		<link>http://oralcancernews.org/wp/connected-nodes-in-throat-cancer-signal-poor-prognosis/</link>
		<comments>http://oralcancernews.org/wp/connected-nodes-in-throat-cancer-signal-poor-prognosis/#comments</comments>
		<pubDate>Thu, 02 Feb 2012 00:10:15 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Head and Neck surgery]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[oropharyngeal squamous cell carcinoma]]></category>
		<category><![CDATA[radiation therapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12403</guid>
		<description><![CDATA[Source: OncologyNurseAdvisor.com The presence of “matted” lymph nodes in persons with oropharyngeal squamous cell carcinoma (SCC)—that is, nodes that are connected together—was associated with a 3-year survival rate of 69%, compared with 94% among patients without matted nodes. Such a marker could help clinicians identify patients who are at heightened risk for metastasis and who [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/connected-nodes-in-throat-cancer-signal-poor-prognosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Queensland researchers make cancer treatment breakthrough</title>
		<link>http://oralcancernews.org/wp/queensland-researchers-make-cancer-treatment-breakthrough/</link>
		<comments>http://oralcancernews.org/wp/queensland-researchers-make-cancer-treatment-breakthrough/#comments</comments>
		<pubDate>Thu, 02 Feb 2012 00:06:54 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Australian Centre for Vaccine Development]]></category>
		<category><![CDATA[cancer cells]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[immune system]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[nasopharyngeal carcinoma]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[throat cancer]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12401</guid>
		<description><![CDATA[Source: HealthCanal.com The culmination of 10 years of collaborative research between scientists from the Queensland Institute of Medical Research (QIMR) and The University of Hong Kong (HKU) Li Ka Shing Faculty of Medicine has led to a significant breakthrough in the treatment of nasopharyngeal carcinoma (NPC), an aggressive throat cancer with a high prevalence in [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/queensland-researchers-make-cancer-treatment-breakthrough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jaw Necrosis Common after Radiation for Oral Cancer</title>
		<link>http://oralcancernews.org/wp/jaw-necrosis-common-after-radiation-for-oral-cancer/</link>
		<comments>http://oralcancernews.org/wp/jaw-necrosis-common-after-radiation-for-oral-cancer/#comments</comments>
		<pubDate>Wed, 01 Feb 2012 23:33:20 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Multidisciplinary Head and Neck Cancer Symposium]]></category>
		<category><![CDATA[oral cancer]]></category>
		<category><![CDATA[osteradionecrosis]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[University of Texas MD And]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12395</guid>
		<description><![CDATA[Source: MedpageToday.com Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco. &#160; &#160; Action Points Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. Explain that osteoradionecrosis of the jaw [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/jaw-necrosis-common-after-radiation-for-oral-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Squamous cell subgroups respond differently to treatment</title>
		<link>http://oralcancernews.org/wp/squamous-cell-subgroups-respond-differently-to-treatment/</link>
		<comments>http://oralcancernews.org/wp/squamous-cell-subgroups-respond-differently-to-treatment/#comments</comments>
		<pubDate>Sat, 28 Jan 2012 15:33:41 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[extracapsular spread]]></category>
		<category><![CDATA[lymph nodes]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[resection margins]]></category>
		<category><![CDATA[survival rates]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12388</guid>
		<description><![CDATA[Source: www.medscape.com Author: Nancy A. Melville A long-term follow-up of patients with head and neck squamous cell carcinoma suggests that only certain high-risk subgroups benefit from radiation plus chemotherapy. This information will spare patients who will not benefit from undergoing the additional treatment. According to the study, presented here at the 2012 Multidisciplinary Head and [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/squamous-cell-subgroups-respond-differently-to-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Third Head and Neck Indication for Erbitux</title>
		<link>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/</link>
		<comments>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/#comments</comments>
		<pubDate>Thu, 05 Jan 2012 18:03:40 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[colorectal cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>
		<category><![CDATA[squamous cell head and neck cancer]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12267</guid>
		<description><![CDATA[Source: The ASCO Post, January 1, 2012, Volume 3, Issue 1, Matthew Stenger &#160; In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.Cetuximab (Erbitux) was recently approved by the FDA for use in combination with platinum-based therapy [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Distant Metastases in Head-and-Neck Squamous Cell Carcinoma Treated with Intensity-modulated Radiotherapy</title>
		<link>http://oralcancernews.org/wp/distant-metastases-in-head-and-neck-squamous-cell-carcinoma-treated-with-intensity-modulated-radiotherapy/</link>
		<comments>http://oralcancernews.org/wp/distant-metastases-in-head-and-neck-squamous-cell-carcinoma-treated-with-intensity-modulated-radiotherapy/#comments</comments>
		<pubDate>Tue, 27 Dec 2011 19:48:17 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[distant metastasis]]></category>
		<category><![CDATA[Head and neck squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12238</guid>
		<description><![CDATA[Source: International Journal of Radiation Oncology, Biology and Physics (IJROBP Online) December 2011 PURPOSE: To determine the pattern and risk factors for distant metastases in head-and-neck squamous cell carcinoma (HNSCC) after curative treatment with intensity-modulated radiotherapy (IMRT). METHODS AND MATERIALS: This was a retrospective study of 284 HNSCC patients treated in a single institution with IMRT. [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/distant-metastases-in-head-and-neck-squamous-cell-carcinoma-treated-with-intensity-modulated-radiotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quality-of-Life Outcomes in Transoral Robotic Surgery</title>
		<link>http://oralcancernews.org/wp/quality-of-life-outcomes-in-transoral-robotic-surgery/</link>
		<comments>http://oralcancernews.org/wp/quality-of-life-outcomes-in-transoral-robotic-surgery/#comments</comments>
		<pubDate>Tue, 27 Dec 2011 17:58:43 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>
		<category><![CDATA[TORS]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12227</guid>
		<description><![CDATA[Source: SAGE Journals Online Abstract Objective. To report long-term, health-related quality-of-life (HRQOL) outcomes in patients treated with transoral robotic surgery (TORS). Study Design. Prospective, longitudinal, clinical study on functional and HRQOL outcomes in TORS. Setting. University tertiary care facility. Subjects and Methods. Patients who underwent TORS were asked to complete a Head and Neck Cancer [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/quality-of-life-outcomes-in-transoral-robotic-surgery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Consider dental issues before beginning cancer treatment</title>
		<link>http://oralcancernews.org/wp/consider-dental-issues-before-beginning-cancer-treatment/</link>
		<comments>http://oralcancernews.org/wp/consider-dental-issues-before-beginning-cancer-treatment/#comments</comments>
		<pubDate>Thu, 22 Dec 2011 22:08:57 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[bacteria]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[oral hygiene]]></category>
		<category><![CDATA[oral mucositis]]></category>
		<category><![CDATA[osteonecrosis]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[saliva]]></category>
		<category><![CDATA[tooth decay]]></category>
		<category><![CDATA[xerostomia]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12217</guid>
		<description><![CDATA[Soure: www.curetoday.com/ Author: Lacey Meyer Dentists advise resolving tooth and gum issues before starting cancer treatment. Bettye Davis admits she has never had very good teeth. But when she received a diagnosis of salivary gland cancer, she was surprised that her oncologist recommended she visit a dentist before beginning radiation treatments to her jaw. “When [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/consider-dental-issues-before-beginning-cancer-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UI professors: HPV editorial misses the mark</title>
		<link>http://oralcancernews.org/wp/ui-professors-hpv-editorial-misses-the-mark/</link>
		<comments>http://oralcancernews.org/wp/ui-professors-hpv-editorial-misses-the-mark/#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:31:17 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[cervical cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[HPV vaccines]]></category>
		<category><![CDATA[Pap smears]]></category>
		<category><![CDATA[radiation]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12177</guid>
		<description><![CDATA[Source: The Daily Iowan The Nov. 29 editorial &#8220;Recommend Pap smears, not vaccines, to prevent cervical cancer&#8221; completely missed the mark with regard to HPV vaccines. We are researchers and clinicians at the University of Iowa who study and treat HPV and other infectious diseases. It is disturbing to think that the article might dissuade [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/ui-professors-hpv-editorial-misses-the-mark/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>FDA Approves Cetuximab for Late-Stage Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 18:05:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12059</guid>
		<description><![CDATA[Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US FDA approval for expanded use of Erbitux</title>
		<link>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/</link>
		<comments>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 13:24:41 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[5-fluorouracil]]></category>
		<category><![CDATA[apoptosis]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[infusion]]></category>
		<category><![CDATA[monoclonal antibody]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12055</guid>
		<description><![CDATA[Source: www.pharmabiz.com Author: staff The US Food and Drug Administration (FDA) has approved Erbitux (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). The approval, which is based on data from the landmark EXTREME (ErbituX in first-line [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Cetuximab for Metastatic Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/#comments</comments>
		<pubDate>Tue, 08 Nov 2011 19:00:48 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[American Society of clinical oncology]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12042</guid>
		<description><![CDATA[Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and neck cancer. Data show that when combined with cisplatin-based chemotherapy, cetuximab improved overall survival, compared with chemotherapy alone. According to the researchers, this is [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>EU grants orphan drug status to BioAlliance Pharma&#8217;s clonidine Lauriad</title>
		<link>http://oralcancernews.org/wp/eu-grants-orphan-drug-status-to-bioalliance-pharmas-clonidine-lauriad/</link>
		<comments>http://oralcancernews.org/wp/eu-grants-orphan-drug-status-to-bioalliance-pharmas-clonidine-lauriad/#comments</comments>
		<pubDate>Sun, 06 Nov 2011 17:14:20 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[clonidine]]></category>
		<category><![CDATA[Lauriad]]></category>
		<category><![CDATA[oral mucositis]]></category>
		<category><![CDATA[orphan drug]]></category>
		<category><![CDATA[radiotherapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12018</guid>
		<description><![CDATA[Source: www.pharmabiz.com Author: staff European Commission has granted orphan drug designation to BioAlliance Pharma SA&#8217;s clonidine Lauriad for prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer. Oral mucositis is a very frequent inflammation of the oral mucosa in head and neck cancer patients treated with radio- and chemotherapy (98,000 new patients [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/eu-grants-orphan-drug-status-to-bioalliance-pharmas-clonidine-lauriad/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Proper dental care for cancer patients: why it is important</title>
		<link>http://oralcancernews.org/wp/proper-dental-care-for-cancer-patients-why-it-is-important/</link>
		<comments>http://oralcancernews.org/wp/proper-dental-care-for-cancer-patients-why-it-is-important/#comments</comments>
		<pubDate>Sun, 23 Oct 2011 16:33:21 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[dental caries]]></category>
		<category><![CDATA[dry mouth]]></category>
		<category><![CDATA[fluoride]]></category>
		<category><![CDATA[neutral pH fluoride]]></category>
		<category><![CDATA[osteoradionecrosis]]></category>
		<category><![CDATA[Parotid gland]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[trismus]]></category>
		<category><![CDATA[xerostomia]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11958</guid>
		<description><![CDATA[Source: newcanaan.patch.com Author: Alan B. Sheiner DDS Common side effects from radiation therapy are not stressed enough in dental schools, but they can be managed and even prevented. A few weeks ago, I was contacted by a retired physician with whom I had not spoken for a number of years since he retired from practice [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/proper-dental-care-for-cancer-patients-why-it-is-important/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

